Chimerix And FDA’s Compassionate-Use Solution
This article was originally published in The Pink Sheet Daily
Executive Summary
A media storm is over and Chimerix has resumed focus on the Phase III trial of its lead program, thanks to quick work by the company and FDA to design a trial providing access to brincidofovir in immunocompromised patients with adenovirus.
You may also be interested in...
FDA Policy Says Right-to-Try Talks Are Between Providers, Sponsors
New internal policy says the US agency cannot force a drug maker to supply an unapproved drug to a patient for expanded access and that the provider must seek company approval to provide the product.
'Right To Try' And PDUFA VI: Patient Advocates, Industry Fight Senate Add-On
Given that 'right to try' is intended to be a patient-centered proposal, patient organizations are a strong voice in opposition, working behind the scenes to revise – or entirely exclude – the legislation as part of the user fee package. But the bill also has powerful advocates among Senate Republicans and in the Trump Administration.
US FDA’s October Outlook: Xphozah After Dispute, Santhera’s New Steroid For DMD, & Plenty Of Pfizer
Fourteen user fee goal dates are on the October calendar, including three novel agents, according to the Pink Sheet US FDA Performance Tracker.